Sign Up to like & get
recommendations!
0
Published in 2019 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2019.02083
Abstract: One major concern when treating patients with ICBs, such as anti-PD1 and anti-CTLA-4 antibodies, is the high frequency of immune-related adverse events. This, along with lacking a reliable biomarker for patient stratification, underscores the need…
read more here.
Keywords:
approaches enhance;
combinatorial approaches;
editorial combinatorial;
anti tumor ... See more keywords